<p><em>推進可擴展的可重複細胞治療和先進細胞培養工作流程</em></p>
<ul>
<li>新的熱穩定和超活性蛋白質，涵蓋成纖維生長因子和白細胞介素細胞因子家族，擴展了 R&amp;D Systems™ 人工智能設計蛋白質組合</li>
<li>人工智能引導的蛋白質設計支持在複雜細胞培養工作流程中提高一致性、性能和可擴展性</li>
<li>工程化信號蛋白有助於解決從發現到製造的細胞治療擴展中的關鍵挑戰</li>
</ul>
<p>, /PRNewswire/ -- Bio-Techne Corporation（納斯達克：TECH），全球生命科學工具、試劑和診斷產品的提供商，今天宣佈推出 R&amp;D Systems™ 人工智能設計蛋白質組合的新成員，旨在提高先進細胞培養和細胞治療開發工作流程中的可重複性和性能。</p>
<p>R&amp;D Systems 人工智能設計蛋白質平台使研究人員能夠設計和創建新的基於蛋白質的解決方案，以幫助克服當前在先進細胞培養中存在的變異性和可擴展性挑戰，通過提高關鍵試劑的穩定性和活性。</p>
<p>通過改善蛋白質的性能特徵，如熱穩定性、活性和溶解度，Bio-Techne 幫助研究人員在從發現到治療開發的過程中實現一致的結果和可擴展的工作流程。這些改進在細胞治療和類器官系統向臨牀和商業規模發展時至關重要，因為細胞信號輸入的微小變化可能會顯著影響結果。</p>
<p>這些新增產品基於 Bio-Techne 的戰略，旨在開發全面的下一代信號技術組合，此前 R&amp;D Systems 人工智能設計蛋白質組合已進行擴展。這些創新，包括超活性細胞因子、熱穩定生長因子和信號通路激動劑，支持幹細胞培養、類器官開發和再生醫學工作流程，通過在基礎研究到工藝開發和規模化生產的整個過程中實現更可控、可重複的系統。</p>
<p>R&amp;D Systems 人工智能設計蛋白質的早期採用者已經在要求嚴格的應用中看到細胞擴增和整體工作流程性能的可測量提升：</p>
<p>“許多患者來源的腫瘤浸潤淋巴細胞（TIL）樣本在初始擴增過程中由於細胞擴增不足而失敗，” 明尼蘇達大學兒科血液腫瘤學系副教授 Branden Moriarity 博士説。“IL-2 熱穩定激動蛋白為 TIL 樣本提供了有希望的增殖優勢，同時也提供了明顯的操作優勢，可以降低 TIL 治療的商品成本。”</p>
<p>這一現實反饋突顯了 R&amp;D Systems 人工智能設計蛋白質平台的更廣泛潛力。隨着最新擴展包括額外的細胞因子和生長因子，該平台旨在實現更一致、可擴展和成本效益高的先進細胞培養工作流程。</p>
<p>“隨着細胞治療從早期研究向臨牀和商業製造的推進，在日益複雜的工作流程中實現一致性、穩健性和可擴展性至關重要，” Bio-Techne 蛋白質科學部門總裁 Will Geist 説。“我們的人工智能設計蛋白質旨在通過提供增強的穩定性、活性和性能來克服這些挑戰，從而實現更可重複的結果，並支持從發現到生產的無縫擴展。”</p>
<p><strong>新推出的蛋白質包括：</strong></p>
<ul>
<li>FGF-4 熱穩定 – 旨在支持多能幹細胞維持、胚胎髮育研究和需要持續生長因子活性的分化工作流程。</li>
<li>FGF-7 熱穩定 – 工程化以支持上皮和組織再生工作流程，包括需要在高温下保持穩定性的先進 3D 培養系統和類器官擴展。</li>
<li>FGF-8b 熱穩定 – 針對發育生物學、類器官建模和再生醫學應用進行了優化，在這些應用中，精確的形態信號至關重要。</li>
<li>IL-3 熱穩定 – 旨在支持造血幹細胞和祖細胞在早期階段和譜系承諾細胞羣體中的擴增和分化，要求在培養中保持細胞因子的穩定性。</li>
<li>IL-15 超活性 – 工程化以驅動 NK 細胞和 T 細胞的擴增，支持細胞治療工作流程和免疫治療研究，在這些領域，增強的信號強度和持久性至關重要。</li>
</ul>
<p>人工智能設計蛋白質組合的擴展鞏固了 Bio-Techne 在開發高性能信號分子以支持先進生物系統方面的領導地位。這些創新支持類器官培養、幹細胞分化和細胞治療製造；在這些領域，從發現到生產的可重複擴展越來越成為成功的必要條件。</p>
<p>有關人工智能設計蛋白質組合的更多信息，請訪問 R&amp;D Systems 網站。</p>
<p><strong>關於 Bio-Techne</strong></p>
<p>Bio-Techne Corporation（納斯達克：TECH）是一家全球生命科學公司，總部位於明尼蘇達州，慶祝成立 50 年，致力於賦能科學和診斷社區以獲得更好的答案。該公司提供高質量的試劑、分析儀器和精準診斷。其產品組合分為三個以客户為中心的品牌：R&amp;D Systems™、Bio-Techne Spatial™ 和 Bio-Techne Diagnostics™，反映了從發現到轉化研究再到臨牀決策的科學旅程。Bio-Techne 在全球 34 個地點運營，僱傭超過 3000 名員工。在 2025 財年，該公司實現淨銷售額超過 12 億美元。其超過 500,000 種產品在全球範圍內被學術研究人員、生物製藥和生物技術公司以及臨牀診斷實驗室使用。</p>
<p>有關 Bio-Techne 及其品牌的更多信息，請訪問 www.bio-techne.com 或在社交媒體上關注該公司，LinkedIn 和 X。</p>
<p>媒體聯繫人：</p>
<p>企業傳播</p>
<p>media.relations@bio-techne.com</p>
<p>David Clair，副總裁</p>
<p>投資者關係</p>
<p>IR@bio-techne.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mmx.prnewswire.com/media/MS667889/Bio-Techne-Corporation-logo-Logo.jpg/query-aWQ9T0EyNzUzOTA5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mmx.prnewswire.com/media/MS667889/Bio-Techne-Corporation-logo-Logo.jpg/query-aWQ9T0EyNzUzOTA5"/></p>
<p>來源：Bio-Techne Corporation</p>

TECH

<p>Bio-Techne 公司（納斯達克代碼：TECH）宣佈推出其 R&D Systems AI-Engineered Designer Protein 產品組合的新成員。這些熱穩定且超活躍的蛋白質，包括 FGF 和 IL 變體，旨在提高先進細胞培養和細胞治療工作流程中的可重複性、穩定性和可擴展性。早期用户報告在細胞擴增和成本效率方面取得了提升，支持從發現到商業生產的過渡</p>

<p><em>Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows</em></p>
<div class="lb-trans"><p><em>推進可擴展的可重複細胞治療和先進細胞培養工作流程</em></p>
</div><ul>
<li>New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&amp;D Systems™ AI-Engineered Designer Protein portfolio</li>
<li>AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows</li>
<li>Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing</li>
</ul>
<div class="lb-trans"><ul>
<li>新的熱穩定和超活性蛋白質，涵蓋成纖維生長因子和白細胞介素細胞因子家族，擴展了 R&amp;D Systems™ 人工智能設計蛋白質組合</li>
<li>人工智能引導的蛋白質設計支持在複雜細胞培養工作流程中提高一致性、性能和可擴展性</li>
<li>工程化信號蛋白有助於解決從發現到製造的細胞治療擴展中的關鍵挑戰</li>
</ul>
</div><p>, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&amp;D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Bio-Techne Corporation（納斯達克：TECH），全球生命科學工具、試劑和診斷產品的提供商，今天宣佈推出 R&amp;D Systems™ 人工智能設計蛋白質組合的新成員，旨在提高先進細胞培養和細胞治療開發工作流程中的可重複性和性能。</p>
</div><p>The R&amp;D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.</p>
<div class="lb-trans"><p>R&amp;D Systems 人工智能設計蛋白質平台使研究人員能夠設計和創建新的基於蛋白質的解決方案，以幫助克服當前在先進細胞培養中存在的變異性和可擴展性挑戰，通過提高關鍵試劑的穩定性和活性。</p>
</div><p>By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes.</p>
<div class="lb-trans"><p>通過改善蛋白質的性能特徵，如熱穩定性、活性和溶解度，Bio-Techne 幫助研究人員在從發現到治療開發的過程中實現一致的結果和可擴展的工作流程。這些改進在細胞治療和類器官系統向臨牀和商業規模發展時至關重要，因為細胞信號輸入的微小變化可能會顯著影響結果。</p>
</div><p>These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&amp;D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing.</p>
<div class="lb-trans"><p>這些新增產品基於 Bio-Techne 的戰略，旨在開發全面的下一代信號技術組合，此前 R&amp;D Systems 人工智能設計蛋白質組合已進行擴展。這些創新，包括超活性細胞因子、熱穩定生長因子和信號通路激動劑，支持幹細胞培養、類器官開發和再生醫學工作流程，通過在基礎研究到工藝開發和規模化生產的整個過程中實現更可控、可重複的系統。</p>
</div><p>Early adopters of R&amp;D Systems AI-Engineered Designer Proteins are already seeing measurable gains in cell expansion and overall workflow performance across demanding applications:</p>
<div class="lb-trans"><p>R&amp;D Systems 人工智能設計蛋白質的早期採用者已經在要求嚴格的應用中看到細胞擴增和整體工作流程性能的可測量提升：</p>
</div><p>&#34;Many patient-derived Tumor-Infiltrating Lymphocytes (TIL) samples fail during initial outgrowth due to insufficient cell expansion,&#34; said Dr Branden Moriarity, Associate Professor in the Division of Pediatric Hematology/Oncology, University of Minnesota. &#34;IL-2 Heat Stable Agonist Protein provides a promising proliferation advantage to TIL samples and also provides clear operational advantages that would reduce the cost of goods for TIL therapies.&#34;</p>
<div class="lb-trans"><p>“許多患者來源的腫瘤浸潤淋巴細胞（TIL）樣本在初始擴增過程中由於細胞擴增不足而失敗，” 明尼蘇達大學兒科血液腫瘤學系副教授 Branden Moriarity 博士説。“IL-2 熱穩定激動蛋白為 TIL 樣本提供了有希望的增殖優勢，同時也提供了明顯的操作優勢，可以降低 TIL 治療的商品成本。”</p>
</div><p>This real-world feedback underscores the broader potential of the R&amp;D Systems AI-Engineered Designer Protein platform. With its latest expansion to include additional cytokines and growth factors, the platform is designed to enable more consistent, scalable, and cost-efficient advanced cell culture workflows.</p>
<div class="lb-trans"><p>這一現實反饋突顯了 R&amp;D Systems 人工智能設計蛋白質平台的更廣泛潛力。隨着最新擴展包括額外的細胞因子和生長因子，該平台旨在實現更一致、可擴展和成本效益高的先進細胞培養工作流程。</p>
</div><p>&#34;As cell therapy advances from early research into clinical and commercial manufacturing, achieving consistency, robustness, and scalability across increasingly complex workflows is critical,&#34; said Will Geist, President of Bio-Techne's Protein Science Segment. &#34;Our AI-Engineered Designer Proteins are designed to overcome these challenges by delivering enhanced stability, activity, and performance—enabling more reproducible results and supporting seamless scale-up from discovery through production.&#34;</p>
<div class="lb-trans"><p>“隨着細胞治療從早期研究向臨牀和商業製造的推進，在日益複雜的工作流程中實現一致性、穩健性和可擴展性至關重要，” Bio-Techne 蛋白質科學部門總裁 Will Geist 説。“我們的人工智能設計蛋白質旨在通過提供增強的穩定性、活性和性能來克服這些挑戰，從而實現更可重複的結果，並支持從發現到生產的無縫擴展。”</p>
</div><p><strong>The newly launched proteins include:</strong></p>
<div class="lb-trans"><p><strong>新推出的蛋白質包括：</strong></p>
</div><ul>
<li>FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity.</li>
<li>FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures.</li>
<li>FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical.</li>
<li>IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture.</li>
<li>IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital.</li>
</ul>
<div class="lb-trans"><ul>
<li>FGF-4 熱穩定 – 旨在支持多能幹細胞維持、胚胎髮育研究和需要持續生長因子活性的分化工作流程。</li>
<li>FGF-7 熱穩定 – 工程化以支持上皮和組織再生工作流程，包括需要在高温下保持穩定性的先進 3D 培養系統和類器官擴展。</li>
<li>FGF-8b 熱穩定 – 針對發育生物學、類器官建模和再生醫學應用進行了優化，在這些應用中，精確的形態信號至關重要。</li>
<li>IL-3 熱穩定 – 旨在支持造血幹細胞和祖細胞在早期階段和譜系承諾細胞羣體中的擴增和分化，要求在培養中保持細胞因子的穩定性。</li>
<li>IL-15 超活性 – 工程化以驅動 NK 細胞和 T 細胞的擴增，支持細胞治療工作流程和免疫治療研究，在這些領域，增強的信號強度和持久性至關重要。</li>
</ul>
</div><p>The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success.</p>
<div class="lb-trans"><p>人工智能設計蛋白質組合的擴展鞏固了 Bio-Techne 在開發高性能信號分子以支持先進生物系統方面的領導地位。這些創新支持類器官培養、幹細胞分化和細胞治療製造；在這些領域，從發現到生產的可重複擴展越來越成為成功的必要條件。</p>
</div><p>For more information about the AI-Engineered Designer Protein portfolio, visit the R&amp;D Systems website.</p>
<div class="lb-trans"><p>有關人工智能設計蛋白質組合的更多信息，請訪問 R&amp;D Systems 網站。</p>
</div><p><strong>ABOUT BIO-TECHNE</strong></p>
<div class="lb-trans"><p><strong>關於 Bio-Techne</strong></p>
</div><p>Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&amp;D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.</p>
<div class="lb-trans"><p>Bio-Techne Corporation（納斯達克：TECH）是一家全球生命科學公司，總部位於明尼蘇達州，慶祝成立 50 年，致力於賦能科學和診斷社區以獲得更好的答案。該公司提供高質量的試劑、分析儀器和精準診斷。其產品組合分為三個以客户為中心的品牌：R&amp;D Systems™、Bio-Techne Spatial™ 和 Bio-Techne Diagnostics™，反映了從發現到轉化研究再到臨牀決策的科學旅程。Bio-Techne 在全球 34 個地點運營，僱傭超過 3000 名員工。在 2025 財年，該公司實現淨銷售額超過 12 億美元。其超過 500,000 種產品在全球範圍內被學術研究人員、生物製藥和生物技術公司以及臨牀診斷實驗室使用。</p>
</div><p>For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn and X.</p>
<div class="lb-trans"><p>有關 Bio-Techne 及其品牌的更多信息，請訪問 www.bio-techne.com 或在社交媒體上關注該公司，LinkedIn 和 X。</p>
</div><p>MEDIA CONTACTS:</p>
<div class="lb-trans"><p>媒體聯繫人：</p>
</div><p>Corporate Communications</p>
<div class="lb-trans"><p>企業傳播</p>
</div><p>media.relations@bio-techne.com</p>
<div class="lb-trans"><p>media.relations@bio-techne.com</p>
</div><p>David Clair, Vice President</p>
<div class="lb-trans"><p>David Clair，副總裁</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>IR@bio-techne.com</p>
<div class="lb-trans"><p>IR@bio-techne.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mmx.prnewswire.com/media/MS667889/Bio-Techne-Corporation-logo-Logo.jpg/query-aWQ9T0EyNzUzOTA5" alt="" original-src="https://mmx.prnewswire.com/media/MS667889/Bio-Techne-Corporation-logo-Logo.jpg?id=OA2753909"/></p>
<p>SOURCE Bio-Techne Corporation</p>
<div class="lb-trans"><p>來源：Bio-Techne Corporation</p>
</div>

Bio-Techne 推出擴展的 R&D Systems AI 設計蛋白質產品組合 | TECH 股票新聞